ClinicalTrials.gg
CompletedNCT00328653Updated Dec 14, 2021Results posted

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)

A Phase 2/3 interventional study of Cyclosporine NOVA22007 0.05% and Cyclosporine NOVA22007 0.1% in Conjunctivitis, Vernal, sponsored by Santen SAS. Completed at 1 site in France. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2021-12-14.

Sponsored by Santen SAS (part of Santen Pharmaceutical Co., Ltd.) · Phase 2/3 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Conjunctivitis, Allergic with a site in France — 1 open to participants now, 1 under way, 1 of them phase 3. Conjunctivitis, Allergic · France.

Started
2006
the only one that year
Phase 2/3
Only one
of the 10
Registered
1st of 10
by date
Lead sponsor
2 of 10
Santen SAS

Among the 10 studies in Conjunctivitis, Allergic with a site in France, this one is the only one that started in 2006, is the only one in phase 2/3, and was the 1st registered.

Conjunctivitis, Allergic

211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.

Browse Conjunctivitis, Allergic studies →

Open to participants now

1 of the 10 studies in Conjunctivitis, Allergic with a site in France is open now. Recruiting first, the newest first:

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Conjunctivitis, Allergic with a site in France, or all of them as a file.
02

Study summary

The primary objective of this study is:

  • To assess the efficacy of Nova22007, a cyclosporine A (CsA), 0.05% and 0.1% versus vehicle in patients with vernal keratoconjunctivitis (VKC) after a 4-week treatment period.

The secondary objectives of this study are:

  • To compare the safety and ocular tolerance of Nova22007 0.05% and 0.1%;
  • To assess the long term safety and ocular tolerance of Nova22007 0.05% and 0.1%; and
  • To assess the decrease in frequency of concomitant artificial tears use.
03

Conditions studied

  • Conjunctivitis, Vernal

Keywords

  • vernal keratoconjunctivitis (VKC), eye, allergy, cyclosporin
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least the two following signs, in at least one eye* (the same eye should fulfill both criteria):

    • Presence of giant papillae with a diameter ≥ 1 mm on the upper tarsal conjunctiva AND
    • Superficial keratitis
  • At least two of the following ocular symptoms with a score > 2 in at least one eye*: burning/stinging, tearing, itching, pain, sticky eyelids, foreign body sensation, mucus discharge, and photophobia.
  • Hyperemia score equal to or greater than 2.

Exclusion criteria

Exclusion Criteria:

  • Concomitant corneal ulcer of infectious origin.
  • Active ocular herpes
  • Disease that could possibly interfere with the interpretation of the study results: active uveitis (defined by Tyndall score > 0), previous history of ocular hypertension or glaucoma, or condition incompatible with the frequent assessments needed by the study.
  • Active herpes.
  • History of or a recurrence in the last 5 years.
  • Abnormality of nasolacrimal drainage apparatus.
  • Concomitant disease not stabilized within 1 month before Screening Visit (e.g. diabetes with glycemia out of range, trouble with thyroid secretions, etc.) or judged by the investigator to be incompatible with the study (e.g. current systemic infections), or condition incompatible with the frequent assessments needed by the study.
  • Known to one of the components of the medicinal products (IMP) or test products.
  • Severe systemic allergy requiring systemic treatment at study entry.
  • Female of .
  • History of drug or alcohol addiction (> 50g/day, 5 glasses alcohol/day).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2 / Phase 3
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
118 participants (actual)

Study arms

  • Experimental
    NOVA22007 0.05%

    four times daily

    Drug: Cyclosporine NOVA22007 0.05%

  • Experimental
    NOVA22007 0.1%

    four times daily

    Drug: Cyclosporine NOVA22007 0.1%

  • Sham comparator
    Vehicle

    administered four times daily

    Drug: Vehicle

Interventions

  • DrugCyclosporine NOVA22007 0.05%
  • DrugCyclosporine NOVA22007 0.1%
  • DrugVehicle
06

What researchers measure

Primary outcomes

  1. Overall Rating of Subjective Symptoms of VKC in Period I

    The primary criteria of the trial was the overall rating of subjective symptoms in ocular symptoms of VKC as compared to Baseline and assessed at Week 4 (Month 1) based on a five-point scale based on BenEzra trial (BenEzra 1986): 1. = Overall worsening of the subjective findings. 2. = No change in the symptoms. 3. = Slight improvement with the child still unable to participate in all normal daily activities. 4. = Marked improvement despite temporary mild itching or mucus discharge. 5. = Completely free of all symptoms.

    Time frame: Week 4

  2. Overall Rating of Objective Symptoms of VKC in Period I

    Overall rating of objective signs was to be assessed under the slit lamp by the Investigator and recorded on a five-point scale based on BenEzra trial (BenEzra 1986): 1. Intense congestion of conjunctival vessels, perilimbal injection, or corneal involvement with the papillary proliferations more extensive or similar to the situation recorded before treatment in at least one of the eyes. 2. The overall condition was assessed as better than before treatment in both eyes. 3. Total re-epithelialisation of the cornea although slight conjunctival and perilimbal hyperaemia and papillary proliferations remains in both eyes. 4. Only slight conjunctival hyperaemia without perilimbal injection or papillary proliferations in at least one eye 5. Both eyes were quiet with no papillary proliferations or conjunctival or perilimbal injection.

    Time frame: Week 4

Secondary outcomes

  1. Change in Mean Daily Number of Unpreserved Artificial Tears Instillations in Period I

    Time frame: Up to Month1

  2. Ocular Tolerance in Period I

    Are the tested eye drops (other than concomitant tear substitute ) comfortable?

    Time frame: Up to Month1

07

Results

Posted Dec 14, 2021

Participant flow

Period I
Participant flow — Period I
MilestoneVehicleNOVA22007 0.05%NOVA22007 0.1%
Started403939
Completed363936
Not completed403
Period II
Participant flow — Period II
MilestoneVehicleNOVA22007 0.05%NOVA22007 0.1%
Started05853
Completed05049
Not completed084

Outcome measures

PrimaryOverall Rating of Subjective Symptoms of VKC in Period I

The primary criteria of the trial was the overall rating of subjective symptoms in ocular symptoms of VKC as compared to Baseline and assessed at Week 4 (Month 1) based on a five-point scale based on BenEzra trial (BenEzra 1986): 1. = Overall worsening of the subjective findings. 2. = No change in the symptoms. 3. = Slight improvement with the child still unable to participate in all normal daily activities. 4. = Marked improvement despite temporary mild itching or mucus discharge. 5. = Completely free of all symptoms.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Overall Rating of Subjective Symptoms of VKC in Period I
ParticipantsVehicleNOVA22007 0.05%NOVA22007 0.1%
1- Overall worsening of the714
2- No change in the symptoms532
3- Slight improvement101511
4- Marked improvement151920
5- Completely free of all symptoms312
Statistical analysis
  • Vehicle vs NOVA22007 0.05% · Cochran-Mantel-Haenszel · p = 0.2699 · M-h chi-square: 1.2187
  • Vehicle vs NOVA22007 0.1% · Cochran-Mantel-Haenszel · p = 0.2719 · M-h chi-square: 1.2359
SecondaryChange in Mean Daily Number of Unpreserved Artificial Tears Instillations in Period I
Time frame:
Up to Month1
Reported as:
Mean · instillations
Change in Mean Daily Number of Unpreserved Artificial Tears Instillations in Period I
instillationsVehicleNOVA22007 0.05%NOVA22007 0.1%
Week1- Baseline-0.5 ± 1.50.1 ± 2.2-0.1 ± 1.3
Week2- Baseline-0.2 ± 0.9-0.4 ± 1.4-0.2 ± 1.5
Month1-Baseline-0.4 ± 1.9-0.5 ± 1.50.0 ± 1.9
SecondaryOcular Tolerance in Period I

Are the tested eye drops (other than concomitant tear substitute ) comfortable?

Time frame:
Up to Month1
Reported as:
Count of participants · Participants
Ocular Tolerance in Period I
ParticipantsVehicleNOVA22007 0.05%NOVA22007 0.1%
Week1 — No3114
Week1 — Yes352434
Week2 — No356
Week2 — Yes343331
Month1 — No287
Month1 — Yes343129
PrimaryOverall Rating of Objective Symptoms of VKC in Period I

Overall rating of objective signs was to be assessed under the slit lamp by the Investigator and recorded on a five-point scale based on BenEzra trial (BenEzra 1986): 1. Intense congestion of conjunctival vessels, perilimbal injection, or corneal involvement with the papillary proliferations more extensive or similar to the situation recorded before treatment in at least one of the eyes. 2. The overall condition was assessed as better than before treatment in both eyes. 3. Total re-epithelialisation of the cornea although slight conjunctival and perilimbal hyperaemia and papillary proliferations remains in both eyes. 4. Only slight conjunctival hyperaemia without perilimbal injection or papillary proliferations in at least one eye 5. Both eyes were quiet with no papillary proliferations or conjunctival or perilimbal injection.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Overall Rating of Objective Symptoms of VKC in Period I
ParticipantsVehicleNOVA22007 0.05%NOVA22007 0.1%
1.Intense congestion of conjunctival vessels, perilimbal injection, or corneal involvement.1887
2.The overall condition was assessed as better than before treatment in both eyes.131716
3.Total re-epithelialisation of the cornea4712
4.Only slight conjunctival hyperaemia in at least one eye462
4.Both eyes were quiet with no papillary proliferations or conjunctival or perilimbal injection.112
Statistical analysis
  • Vehicle vs NOVA22007 0.05% · Cochran-Mantel-Haenszel · p = 0.0386 · M-h-chi-square: 4.2925
  • Vehicle vs NOVA22007 0.1% · Cochran-Mantel-Haenszel · p = 0.0208 · M-h-chi-square: 5.3007

Adverse events

Collected over From the time the patient gave informed consent until the last trial visit at month 4.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/40 (0%)0/40 (0%)14/40 (35%)
Period I- NOVA22007 0.05%0/39 (0%)0/39 (0%)14/39 (35.9%)
Period I-NOVA22007 0.1%0/39 (0%)0/39 (0%)12/39 (30.8%)
Period II- NOVA22007 0.05%0/58 (0%)1/58 (1.7%)17/58 (29.3%)
Period II-NOVA22007 0.1%0/53 (0%)0/53 (0%)11/53 (20.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboPeriod I- NOVA22007 0.05%Period I-NOVA22007 0.1%Period II- NOVA22007 0.05%Period II-NOVA22007 0.1%
ASTHMARespiratory, thoracic and mediastinal disorders0/400/390/391/580/53
Most frequent other events
Showing 10 of 34
Most frequent other events
EventPlaceboPeriod I- NOVA22007 0.05%Period I-NOVA22007 0.1%Period II- NOVA22007 0.05%Period II-NOVA22007 0.1%
Allergic keratitisEye disorders9/403/398/391/580/53
Instillation site pruritusGeneral disorders1/405/394/393/581/53
Instillation Site IrritationGeneral disorders0/404/392/392/584/53
Visual acuity reducedEye disorders1/400/393/393/581/53
Corneal UlcerEye disorders3/400/390/391/580/53
Drug intoleranceGeneral disorders0/402/390/394/581/53
Ocular hyperaemiaEye disorders1/402/392/390/580/53
Instillation site painGeneral disorders2/400/391/390/581/53
BlepharitisEye disorders0/400/391/390/580/53
HyperthermiaGeneral disorders0/401/390/390/580/53

Baseline characteristics

Age, Customized
Age, Customized(years)NOVA22007 0.05%NOVA22007 0.1%VehicleTotal
Age8.5 ± 2.99.4 ± 3.78.5 ± 2.48.8 ± 3.9
Sex: Female, Male
Sex: Female, Male(Participants)NOVA22007 0.05%NOVA22007 0.1%VehicleTotal
Female561122
Male34332996
08

Study locations

1 site
  • Groupe Hospitalier Bichat-Claude Bernard
    Paris, 75018, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006 and a primary completion of Feb 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2021, 14 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2006
First posted
May 22, 2006
Start
May 2006
Primary completionActual
Feb 22, 2007
Results first posted
Dec 14, 2021
Last update
Dec 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00328653
Lead sponsor
Santen SAS
First posted
May 22, 2006
Start date
May 2006
Primary completion
Feb 22, 2007
Results posted
Dec 14, 2021
Last update
Dec 14, 2021

Study contacts

David BenEzra, Pf
principal investigator · Haddassah University Hospital
Christophe Baudouin, Pf.
study director · Hôpital des XV-XX 28 rue de Charenton 75012 Paris
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion